




RealRate

PHARMACEUTICAL 2014

Keryx Biopharmaceuticals INC
Rank 120 of 234



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Keryx Biopharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Keryx Biopharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 69% points. The greatest weakness of Keryx Biopharmaceuticals INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 259%, being 16% points above the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	56,928
Cost of Goods Sold	0
Intangible Assets	3,208
Liabilities, Current	15,328
Liabilities, Non-Current	38
Other Assets	281
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	351
Other Revenues	7,000
Property and Equipment	349
Research and Development	34,734
Selling, General and Administrative Expense	19,349

Output Variable	Value in 1000 USD
Assets	60,766
Liabilities	15,366
Expenses	54,083
Revenues	7,000
Stockholders Equity	45,400
Net Income	-46,732
Comprehensive Net Income	-46,732
BaseVar	68,783
ECR before LimitedLiability	137%
Economic Capital Ratio	259%